OSTEOTECH GRAFTON DRIVES REVENUE GROWTH IN 1997 WITH 74% U.S. SALES INCREASE; KENSEY NASH BREAKS EVEN ON ANGIO-SEAL ROYALTY STREAM IN SECOND QUARTER
This article was originally published in The Gray Sheet
Executive Summary
A 74% domestic sales increase for Osteotech's flagship Grafton demineralized bone matrix product in 1997 to $34.9 mil. led the company to a solid financial performance in the three and 12-month periods ended Dec. 31., as revenues increased 34% to $12.2 mil. and 28% to $36 mil. for the quarter and year, respectively.